GM1 ganglioside for acute ischemic stroke - Trial design issues

Annals of the New York Academy of Sciences

Volumn 845, Issue , 1998, Pages 391-401

  Alter, Milton ^a  

^a LANKENAU HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE GM1; NEUROPROTECTIVE AGENT;

ANIMAL; BRAIN ISCHEMIA; CLINICAL PROTOCOL; DAILY LIFE ACTIVITY; HUMAN; MORTALITY; MOTOR ACTIVITY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVIEW; ABDOMINAL PAIN; CANCER; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFERENCE PAPER; DERMATITIS; DRUG EFFICACY; FEVER; HEADACHE; HYPERKINESIA; INFECTION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; LUNG TOXICITY; META ANALYSIS; NEUROTOXICITY; PRURITUS; RASH; SAMPLE; SEIZURE; SHOULDER HAND SYNDROME; STATISTICAL ANALYSIS; THORAX PAIN; TREATMENT OUTCOME; XEROSTOMIA;

ACTIVITIES OF DAILY LIVING; ANIMALS; BRAIN ISCHEMIA; CLINICAL PROTOCOLS; G(M1) GANGLIOSIDE; HUMANS; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; RANDOMIZED CONTROLLED TRIALS; RECURRENCE;

EID: 0031595130     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1998.tb09691.x     Document Type: Article

References (29)

1. PHILLIS, J. W. & M. H. O'REGAN. 1995. GM, ganglioside inhibits ischemic release of amino acid neurotransmitters from rat cortex. Neuroreport 6: 2010-2012.
2. FRUGONI, P., E. F. SECCHI & C. CHIZZOLINI. 1994. Effect of pure bovine brain-derived gangliosides on normal human B cell proliferation in vitro. J. Neuroimmunol. 49: 189-195.
3. 2+ level. J. Neurosci. Res. 44: 374-380.
4. 1 ganglioside: Involvement of Trk neurotrophin receptors. J. Biol. Chem. 270: 3074-3080.
5. FERRARI, G., A. BATISTATOU & L. A. GREENE. 1993. Gangliosides rescue neuronal cells from death after trophic factor deprivation. J. Neurosci. 13: 1879-1887.
6. 1. Chin. J. Physiol. 39: 211-217.
7. BASSI, S., M. G. ALBIZZATI, M. SBACCHI, L. FRATTOLA & M. MASSAROTTI. 1985. Therapy in stroke: Letter to the Editor. Stroke 16: 899-900.
8. 1 ganglioside in cerebrovascular diseases: A double-blind trial in 40 cases. Eur. Neurol. 24: 343-351.
9. 1 ganglioside therapy in acute ischemic stroke. Cerebrovasc. Dis. 2: 163-168.
10. 1 in acute stroke. J. Neurol. Neurosurg. Psychiatry 51: 1213-1214.
11. 1 in early strokes. Neurol. Neurochir. Pol. 28: 643-649.
12. ARGENTINO, C., M. L. SACCHETTI, D. TONI, G. SAVOINI, E. D'ARCANGELO, F. ERMINIO, F. FEDERICO, F. FERRO MILONE, V. GALLAI, D. GAMBI, A. MAMOLI, G. A. OTTONELLO, O. PONARI, G. REBUCCI, U. SENIN & C. FIESCHI. 1989. GM-1 ganglioside therapy in acute ischemic stroke. Stroke 20: 1143-1149.
13. 1: Efficacy and safety results of the monosialoganglioside early stroke trial. Stroke 23: 519-526.
14. 1 in acute ischemic stroke: The SASS trial. Stroke 25: 1141-1148.
15. COTE, R., R. N. BATTISTA, C. WOLFSON, J. BOUCHER, J. ADAM & V. HACHINSKI. 1989. The Canadian Neurological Scale: Validation and reliability assessment. Neurology 39: 638-643.
16. NORRIS, J. W. 1982. Comments on "Study design of stroke treatments." Stroke 13: 526-528.
17. MAHONEY, F. I. & D. W. BARTHEL. 1995. Functional evaluation: The Barthel Index. Md. State Med. J. 14: 61-64.
18. FUGL-MEYER, A. & L. I. JAASKOL. 1975. The post-stroke hemiplegic patient: A method of evaluation of physical performance. Scand. J. Rehabil. Med. 7: 13-31.
19. SCANDINAVIAN STROKE STUDY GROUP. 1985. Multicenter trial of hemodilution in ischemic stroke: Background and study protocol. Stroke 16: 885-890.
20. FRITHZ, G. & I. WERNER. 1976. Studies on cerebrovascular strokes. Acta Med. Scand. 199: 133-140.
21. 1 after intravenous and intramuscular administration to healthy volunteers. Clin. Pharmacol. Ther. 50: 141-149.
22. 1 ganglioside. Lancet 342: 115.
23. 1 ganglioside-like structure. J. Exp. Med. 178: 1771-1775.
24. GRANIERI, E., I. CASETTA, V. GOVONI, M. R. TOLA, E. PAOLINO & W. A. ROCCA. 1991. Ganglioside therapy and Guillain-Barré syndrome: A historical cohort study in Ferrara, Italy. Neuroepidemiology 10: 161-169.
25. MATIAS-GUIU, J., R. MARTIN, J. BLANQUER, M. J. GONZALEZ, R. FALIP, A. OLTRA & J. M. MOLTO. 1993. Incidence of Guillain-Barré syndrome and ganglioside intake in Alcoi, Spain. Neuroepidemiology 12: 58-60.
26. HARTUNG, H.-P., J. D. POLLARD, G. K. HARVEY & K. V. TOYKA. 1995. Immunopathogenesis and treatment of the Guillain-Barré syndrome-Part I. Muscle & Nerve 18: 137-153.
27. VRETHEM, M., T. SKOGH, G. BERLIN, H. HOLINGREN & J. ERNERUDH. 1991. Antibodies to peripheral nerve myelin may occur without clinical neuropathy in healthy persons. J. Neuroimmunol. 32: 219-222.
28. DIMARTINO, A., J. SAFAR, M. CERONI & C. J. GIBBS, JR. 1992. Purification of non-infectious ganglioside preparations from scrapie-infected brain tissue. Arch. Virol. 124: 111-121.
29. THE NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE-rtPA Stroke Study Group. 1995. Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 33: 1581-1633.